109 related articles for article (PubMed ID: 18779599)
1. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.
Chanan-Khan AA; Whitworth A; Bangia N; Porter CW; Lee K
J Clin Oncol; 2008 Oct; 26(29):4851-2; author reply 4852-3. PubMed ID: 18779599
[No Abstract] [Full Text] [Related]
2. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Moutouh-de Parseval LA; Weiss L; DeLap RJ; Knight RD; Zeldis JB
J Clin Oncol; 2007 Nov; 25(31):5047. PubMed ID: 17971612
[No Abstract] [Full Text] [Related]
3. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
4. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM; Hillmen P; Mahadevan D; Bühler A; Uharek L; Coutré S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
Leuk Lymphoma; 2012 Mar; 53(3):417-23. PubMed ID: 21879809
[TBL] [Abstract][Full Text] [Related]
5. Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
Kosseifi SG; Vyas B; Vyas H; Krishnaswamy G; Smith S
Tenn Med; 2009 Oct; 102(10):33-6. PubMed ID: 19899317
[No Abstract] [Full Text] [Related]
6. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
[TBL] [Abstract][Full Text] [Related]
7. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Miller KC; Musial L; Whitworth A; Chanan-Khan A
Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
[TBL] [Abstract][Full Text] [Related]
9. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Pinto A; Corazzelli G; De Filippi R
Cancer; 2012 Mar; 118(6):1738; author reply 1739. PubMed ID: 21766303
[No Abstract] [Full Text] [Related]
10. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Maddocks K; Ruppert AS; Browning R; Jones J; Flynn J; Kefauver C; Gao Y; Jiang Y; Rozewski DM; Poi M; Phelps MA; Harper E; Johnson AJ; Byrd JC; Andritsos LA
Leuk Res; 2014 Sep; 38(9):1025-9. PubMed ID: 25082342
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Brown JR
Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
13. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
14. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Chanan-Khan A; Miller KC; Lawrence D; Padmanabhan S; Miller A; Hernandez-Illatazurri F; Czuczman MS; Wallace PK; Zeldis JB; Lee K
Cancer; 2011 May; 117(10):2127-35. PubMed ID: 21523725
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Aue G; Njuguna N; Tian X; Soto S; Hughes T; Vire B; Keyvanfar K; Gibellini F; Valdez J; Boss C; Samsel L; McCoy JP; Wilson WH; Pittaluga S; Wiestner A
Haematologica; 2009 Sep; 94(9):1266-73. PubMed ID: 19734418
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in CLL: what is the optimal dose?
Wendtner CM
Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
[No Abstract] [Full Text] [Related]
18. Tumor lysis syndrome in a case of chronic lymphocytic leukemia induced by high-dose corticosteroids.
Coutinho AK; de O Santos M; Pinczowski H; Feher O; del Giglio A
Am J Hematol; 1997 Jan; 54(1):85-6. PubMed ID: 8980269
[No Abstract] [Full Text] [Related]
19. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
20. Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia.
Dizdar O; Yürekli BS; Pürnak T; Aksu S; Haznedaroglu IC
Ann Pharmacother; 2004; 38(7-8):1319-20. PubMed ID: 15138295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
